170353-28-3

Usage

Uses

Used in Pharmaceutical Synthesis:
[1-(Pyridin-2-yl)piperidin-4-yl]methanamine is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, [1-(Pyridin-2-yl)piperidin-4-yl]methanamine serves as a crucial building block for the creation of novel compounds with pesticidal, herbicidal, or fungicidal properties. Its incorporation into these chemicals can lead to enhanced efficacy and selectivity in agricultural applications.
Used as a Ligand in Drug Development:
[1-(Pyridin-2-yl)piperidin-4-yl]methanamine has shown potential as a ligand in the development of new drugs. Its chemical structure allows for the formation of stable complexes with various metal ions, which can be exploited in the design of innovative pharmaceuticals with improved pharmacological properties.
Used in Organic Synthesis as a Building Block:
Due to its versatile chemical reactivity, [1-(Pyridin-2-yl)piperidin-4-yl]methanamine is a valuable tool in organic synthesis. It can be used as a building block to construct more complex molecular structures, which can be applied in various fields, including materials science, chemical research, and the development of new chemical entities with specific functions or properties.

Upstream product

• 109-09-1 2-chloropyridine 
• 123-51-3 i-Amyl alcohol 
• 7144-05-0 4-Aminomethylpiperidine 
• 132431-09-5 benzyl (piperidin-4-ylmethyl)carbamate 
• 372-48-5 2-fluoropyridine 
• 302341-46-4 benzyl ((1-(pyridin-2-yl)piperidin-4-yl)methyl)carbamate 

Relevant academic research and scientific papers

SMARCA INHIBITORS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and/or polybromo-1 (PB-1) protein via ubiqitination and/or degradation by compounds. The compounds are useful in treatment of cancer.

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial

Integrin receptors antagonists

The invention relates to novel compounds which bind to integrin receptors, and to the preparation thereof and the use thereof as drugs.

N-substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as 92 antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents

A series of N-substituted 1-(2,3-dihydro-1,4-benzodioxin-2- yl)methylamine derivatives with D2 antagonist/5-HT(1A) partial agonist activity has been prepared as potential atypical antipsychotic agents. Optimization of in vitro receptor binding activity and in vivo activity in rodent models of psychosis has led to compound 24, which showed good affinities for human D2, D3, and 5-HT(1A) receptors but significantly less affinity for human α1 adrenoceptors and rat H1 and muscarinic receptors. In rodents, 24 showed functional D2-like antagonism and 5-HT(1A) partial agonism. After oral dosing, 24 showed good activity in rodent antipsychotic tests and very little potential to cause extrapyramidal side effects (EPS), as measured by its ability to induce catalepsy in rats only at very high doses. In the light of this promising profile of activity, 24 has been selected for clinical investigation as a novel antipsychotic agent with a predicted low propensity to cause EPS.

Bicyclic aromatic compounds as therapeutic agents

Compounds of formula I STR1 and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; and g is 0, 1, 2, 3 or 4; R1, R2, R3, R4, U, Q and T are defined in claim 1. The compounds have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.